A regimen of boceprevir combined with pegylated interferon-ribavirin
improved sustained virologic response in patients with hepatitis C and
advanced fibrosis and cirrhosis, according to recent study results.
Using two phase 3, randomized double blind studies, researchers assessed the efficacy and safety of triple therapy
— boceprevir (BOC) and peginterferon-ribavirin (PR) — among 178
treatment naive or unresponsive patients with HCV genotype 1 and
advanced F3/F4 Metavir fibrosis scores. Patients assigned to three study
arms received a 4-week lead-in of PR and then either 44 more weeks of
PR plus placebo (PR48), PR in addition to BOC response-guided therapy
(BOC/RGT), or PR plus BOC for 44 weeks (BOC/PR48).